Fig. 1From: Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case reportCorrelative immune studies showing cytokine levels (measured in pg/ml) in peripheral blood at specific time points with combination therapy involving pembrolizumab and tocilizumabBack to article page